The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nikitina M.A.

Siberian State Medical University

Bragina E.Yu.

Scientific Research Institute of Medical Genetics — Tomsk National Research Medical Center of the Russian Academy of Sciences

Nazarenko M.S.

Siberian State Medical University;
Scientific Research Institute of Medical Genetics — Tomsk National Research Medical Center of the Russian Academy of Sciences

Alifirova V.M.

Siberian State Medical University

The association of single-nucleotide polymorphism rs6265 of the brain-derived neurotrophic factor gene with clinical features in Parkinson’s disease

Authors:

Nikitina M.A., Bragina E.Yu., Nazarenko M.S., Alifirova V.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7): 82‑88

DOI: 10.17116/jnevro202412407182

Read: 1600 times

Download PDF (RU)
Contact the author
Table of contents

THE ASSOCIATION OF SINGLE-NUCLEOTIDE POLYMORPHISM RS6265 OF THE BRAIN-DERIVED NEUROTROPHIC FACTOR GENE WITH CLINICAL FEATURES IN PARKINSON’S DISEASE
THE ASSOCIATION OF SINGLE-NUCLEOTIDE POLYMORPHISM RS6265 OF THE BRAIN-DERIVED NEUROTROPHIC FACTOR GENE WITH CLINICAL FEATURES IN PARKINSON’S DISEASE

To cite this article:

Nikitina MA, Bragina EYu, Nazarenko MS, Alifirova VM. The association of single-nucleotide polymorphism rs6265 of the brain-derived neurotrophic factor gene with clinical features in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7):82‑88. (In Russ.)
https://doi.org/10.17116/jnevro202412407182

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Pathomorphosis of the Parkinson’s disease against the background of DBS STN. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):21-27
Asthenia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):5-10
The effect of bila­teral subthalamic nucleus deep brain stimulation on gait and bala­nce in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):94-101
Neuroinflammatory and neurodegenerative aspe­cts of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):102-111
Schi­zophrenic spectrum diso­rders and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):136-141
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Diagnosis of pathological and adaptive bala­nce changes in Parkinson’s disease to select a reha­bilitation program. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):88-94
The state of mental health of migrant workers and citi­zens of the Russian Fede­ration: A comparative analysis as illu­strated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101
Prediction and prevention of burnout syndrome in health care professionals in high epidemic risk settings. Russian Journal of Preventive Medi­cine. 2025;(4):51-56
Abstract:

OBJECTIVE

To evaluate the frequency and severity of various clinical symptoms of Parkinson’s disease (PD) depending on the BDNF rs6265 polymorphism.

MATERIAL AND METHODS

The study included 533 patients with PD. The stage of PD was assessed using the Hoehn and Yahr scale (1967), motor symptoms were evaluated with MDS-UPDRS. Assessment of non-motor symptoms (NMS) in PD was conducted using the Beck Depression Inventory II (BDI-II); the Hospital Anxiety and Depression Scale (HADS); the Apathy Scale; the Montreal Cognitive Assessment (MoCA test); the Questionnaire for Impulsive-Compulsive Disorders in PD -Rating Scale (QUIP-RS). Genotyping of the BDNF variant (rs6265) was performed using real-time PCR with TaqMan probes.

RESULTS

Most PD patients have a combination of NMS increasing as the disease progresses and is determined by molecular-genetic individual characteristics. There are significant differences in the severity of motor symptoms and NMS: individuals with the AA genotype showed significantly pronounced motor symptoms (p<0.0001); emotional-affective symptoms (p<0.0001); cognitive and impulsive behavioral disorders (p<0.0001).

CONCLUSION

The rs6265 BDNF allele A is associated with a wide range of NMS, increasing the risk of their development in patients with PD, thus playing the important role in the etiopathogenesis of this pathology.

Keywords:

Parkinson’s disease
non-motor symptoms
motor manifestations
apathy
anxiety
impulsive behavioral disorders
brain-derived neurotrophic factor
BDNF
rs6265
G196A
Val66Met
neurodegenerative diseases

Authors:

Nikitina M.A.

Siberian State Medical University

Bragina E.Yu.

Scientific Research Institute of Medical Genetics — Tomsk National Research Medical Center of the Russian Academy of Sciences

Nazarenko M.S.

Siberian State Medical University;
Scientific Research Institute of Medical Genetics — Tomsk National Research Medical Center of the Russian Academy of Sciences

Alifirova V.M.

Siberian State Medical University

Received:

19.01.2024

Close metadata

References:

  1. Bonnet AM, Jutras MF, Czernecki V, et al. Nonmotor symptoms in Parkinson’s disease in 2012: relevant clinical aspects. Parkinsons Dis. 2012;2012:198316. https://doi.org/10.1155/2012/198316
  2. Shipilova NN, Titova NV, Katunina EA. The problem of non-motor symptoms of Parkinson’s disease and the effect of dopaminergic therapy on their correction. RMJ. 2018;(4-II):85-90. (In Russ.).
  3. Nikitina MA, Zhukova NG, Bragina EYu, et al. Heterogeneity of non-motor symptoms in patients with Parkinson’s disease in the Tomsk region. Yakut Medical Journal. 2019;3(67):70-74. (In Russ.). https://doi.org/10.25789/YMJ.2019.67.20
  4. Scott BM, Eisinger RS, Burns MR, et al. Co-occurrence of apathy and impulse control disorders in Parkinson disease. Neurology. 2020;95(20):e2769-e2780. https://doi.org/10.1212/WNL.0000000000010965
  5. Palasz E, Wysocka A, Gasiorowska A, et al. BDNF as a Promising Therapeutic Agent in Parkinson’s Disease. Int J Mol Sci. 2020;21(3):1170. https://doi.org/10.3390/ijms21031170
  6. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol. 2001;63(1):71-124.  https://doi.org/10.1016/s0301-0082(00)00014-9
  7. Nguyen VT, Hill B, Sims N, et al. Brain-derived neurotrophic factor rs6265 (Val66Met) single nucleotide polymorphism as a master modifier of human pathophysiology. Neural Regen Res. 2023;18(1):102-106.  https://doi.org/10.4103/1673-5374.343894
  8. Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol. 2014;220:223-250.  https://doi.org/10.1007/978-3-642-45106-5_9
  9. Allen SJ, Watson JJ, Shoemark DK, et al. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther. 2013;138(2):155-175.  https://doi.org/10.1016/j.pharmthera.2013.01.004
  10. Chen ZY, Jing D, Bath KG, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006;314(5796):140-143.  https://doi.org/10.1126/science.1129663
  11. Nassan M, Veldic M, Winham S, et al. Methylation of Brain Derived Neurotrophic Factor (BDNF) Val66Met CpG site is associated with early onset bipolar disorder. J Affect Disord. 2020;267:96-102.  https://doi.org/10.1016/j.jad.2020.02.002
  12. Szarowicz CA, Steece-Collier K, Caulfield ME. New Frontiers in Neurodegeneration and Regeneration Associated with Brain-Derived Neurotrophic Factor and the rs6265 Single Nucleotide Polymorphism. Int J Mol Sci. 2022;23(14):8011. https://doi.org/10.3390/ijms23148011
  13. Nikitina MA, Bragina EYu, Nazarenko MS, et al. The relationship between the rs6265 polymorphism of the BDNF gene and the level of serum neurotrophic factor in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(1):114-120. (In Russ.). https://doi.org/10.17116/jnevro2024124011114
  14. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591-1601. https://doi.org/10.1002/mds.26424
  15. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Movement Disorders. 2007;22(1):41-47.  https://doi.org/10.1002/mds.21198
  16. Beck C, Gable R. Postpartum Depression Screening Scale: Development and Psychometric Testing. Nursing Research. 2000;49(5):272-282.  https://doi.org/10.1097/00006199-200009000-00006
  17. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370.  https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
  18. Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134-139.  https://doi.org/10.1176/jnp.4.2.134
  19. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.  https://doi.org/10.1111/j.1532-5415.2005.53221.x
  20. Evans AH, Okai D, Weintraub D, et al. Members of the International Parkinson and Movement Disorder Society (IPMDS) Rating Scales Review Committee. Scales to assess impulsive and compulsive behaviors in Parkinson’s disease: Critique and recommendations. Mov Disord. 2019;34(6):791-798.  https://doi.org/10.1002/mds.27689
  21. Sal’kov VN, Voronkov DN, Khacheva KK, et al. Clinical and morphological analysis of a caseof Parkinson’s disease. Russian Journal of Archive of Pathology. 2020;82(2):52-56. (In Russ.). https://doi.org/10.17116/patol20208202152
  22. Gorzkowska A, Cholewa J, Cholewa J, et al. Risk Factors for Apathy in Polish Patients with Parkinson’s Disease. Int J Environ Res Public Health. 2021;18(19):10196. https://doi.org/10.3390/ijerph181910196
  23. den Brok MG, van Dalen JW, van Gool WA, et al. Apathy in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord. 2015;30(6):759-769.  https://doi.org/10.1002/mds.26208
  24. Kimura I, Revankar GS, Ogawa K, et al. Neural correlates of impulsive compulsive behaviors in Parkinson’s disease: A Japanese retrospective study. Neuroimage Clin. 2023;37:103307. https://doi.org/10.1016/j.nicl.2022.103307
  25. Weintraub D, Simuni T, Caspell-Garcia C, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov Disord. 2015;30(7):919-927.  https://doi.org/10.1002/mds.26170
  26. Karlsson Linnér R, Biroli P, Kong E, et al. Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. Nat Genet. 2019;51(2):245-257.  https://doi.org/10.1038/s41588-018-0309-3
  27. Baselmans B, Hammerschlag AR, Noordijk S, et al. The Genetic and Neural Substrates of Externalizing Behavior. Biol Psychiatry Glob Open Sci. 2021;2(4):389-399.  https://doi.org/10.1016/j.bpsgos.2021.09.007
  28. Levchenko A, Malov S, Antonik A, et al. A Genome-Wide Association Study Reveals a BDNF-Centered Molecular Network Associated with Alcohol Dependence and Related Clinical Measures. Biomedicines. 2022;10(12):3007. https://doi.org/10.3390/biomedicines10123007
  29. Xu K, Li B, McGinnis KA, et al. Genome-wide association study of smoking trajectory and meta-analysis of smoking status in 842,000 individuals. Nat Commun. 2020;11(1):5302. https://doi.org/10.1038/s41467-020-18489-3
  30. Erzurumluoglu AM, Liu M, Jackson VE, et al. Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. Mol Psychiatry. 2020;25(10):2392-2409. https://doi.org/10.1038/s41380-018-0313-0
  31. Saunders GRB, Wang X, Chen F, et al. Genetic diversity fuels gene discovery for tobacco and alcohol use. Nature. 2022;612(7941):720-724.  https://doi.org/10.1038/s41586-022-05477-4
  32. Białecka M, Kurzawski M, Roszmann A, et al. BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson’s disease. Neurosci Lett. 2014;561:86-90.  https://doi.org/10.1016/j.neulet.2013.12.051
  33. Altmann V, Schumacher-Schuh AF, Rieck M, et al. Val66Met BDNF polymorphism is associated with Parkinson’s disease cognitive impairment. Neurosci Lett. 2016;615:88-91.  https://doi.org/10.1016/j.neulet.2016.01.030
  34. Sampedro F, Marín-Lahoz J, Martínez-Horta S, et al. Pattern of cortical thinning associated with the BDNF Val66Met polymorphism in Parkinson’s disease. Behav Brain Res. 2019;372:112039. https://doi.org/10.1016/j.bbr.2019.112039
  35. van der Kolk NM, Speelman AD, van Nimwegen M, et al. BDNF polymorphism associates with decline in set shifting in Parkinson’s disease. Neurobiol Aging. 2015;36(3):1605.e1-6.  https://doi.org/10.1016/j.neurobiolaging.2014.08.023
  36. Yin Y, Su X, Pan L, Li C. BDNF Val66Met polymorphism and cognitive impairment in Parkinson’s disease-a meta-analysis. Neurol Sci. 2019;40(9):1901-1907. https://doi.org/10.1007/s10072-019-03907-2
  37. Gajewski PD, Hengstler JG, Golka K, et al. The Met-allele of the BDNF Val66Met polymorphism enhances task switching in elderly. Neurobiol Aging. 2011;32(12):2327.e7-19.  https://doi.org/10.1016/j.neurobiolaging.2011.06.010
  38. Fischer DL, Auinger P, Goudreau JL, et al. BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson’s Disease. Neurotherapeutics. 2020;17(4):1785-1795. https://doi.org/10.1007/s13311-020-00965-9
  39. Приинята в печати 02.04.2024 
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.